Movatterモバイル変換


[0]ホーム

URL:


Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Wiley full text link Wiley Free PMC article
Full text links

Actions

Share

.2015 May;110(5):823-31.
doi: 10.1111/add.12850. Epub 2015 Feb 25.

Prolonged hypogonadism in males following withdrawal from anabolic-androgenic steroids: an under-recognized problem

Affiliations

Prolonged hypogonadism in males following withdrawal from anabolic-androgenic steroids: an under-recognized problem

Gen Kanayama et al. Addiction.2015 May.

Abstract

Aims: To assess the frequency and severity of hypogonadal symptoms in male long-term anabolic-androgenic steroid (AAS) misusers who have discontinued AAS use.

Design: Cross-sectional, naturalistic.

Setting: Out-patient facility.

Participants: Twenty-four male former long-term AAS users and 36 non-AAS-using weightlifters, recruited by advertisement in Massachusetts, USA. Five of the former users were currently receiving treatment with physiological testosterone replacement, leaving 19 untreated users for the numerical comparisons below.

Measurements: The Structured Clinical Interview for DSM-IV, questions regarding history of AAS use, physical examination, serum hormone determinations and the International Index of Erectile Function (IIEF).

Findings: Compared with the 36 non-AAS-using weightlifters, the 19 untreated former AAS users displayed significantly smaller testicular volumes [estimated difference, 95% confidence interval (CI) = 2.3 (0.1, 4.5) ml; P = 0.042] and lower serum testosterone levels [estimated difference: 95% CI = 131 (25, 227) dl; P = 0.009], with five users showing testosterone levels below 200 ng/dl despite abstinence from AAS for 3-26 months. Untreated former users also displayed significantly lower scores on the IIEF sexual desire subscale [estimated difference: 95% CI = 2.4 (1.3, 3.4) points on a 10-point scale; P < 0.001]. In the overall group of 24 treated plus untreated former users, seven (29%) had experienced major depressive episodes during AAS withdrawal; four of these had not experienced major depressive episodes at any other time. Two men (8%) had failed to regain normal libidinal or erectile function despite adequate replacement testosterone treatment.

Conclusions: Among long-term anabolic-androgenic steroid misusers, anabolic-androgenic steroid-withdrawal hypogonadism appears to be common, frequently prolonged and associated with substantial morbidity.

Keywords: Anabolic-androgenic steroids; drug withdrawal; erectile function; hypogonadism; libido; men; testosterone.

© 2015 Society for the Study of Addiction.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests

Dr. Pope has provided expert testimony approximately once per year in cases involving anabolic-androgenic steroids. Dr. Pope has received research funding from Shire Pharmaceuticals and Genentech Pharmaceuticals for work unrelated to this manuscript. Dr. Baggish has received research grants from the American Heart Association and American Society of Echocardiography for work unrelated to this manuscript. Dr. Bhasin has received research grants from NIA, NIDDK, NCATS, AbbVie, Regeneron, and Eli Lilly for work unrelated to this manuscript, and has equity interest in Function Promoting Therapies, LLC. Dr. Kanayama, Dr. Weiner, Mr. DeLuca, and Ms. Isaacs report no interests.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kanayama G, Hudson JI, Pope HG. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern? Drug Alcohol Depend. 2008;98:1–12. - PMC - PubMed
    1. Tan RS, Scally MC. Anabolic steroid-induced hypogonadism--towards a unified hypothesis of anabolic steroid action. Med Hypotheses. 2009;72:723–8. - PubMed
    1. de Souza GL, Hallak J. Anabolic steroids and male infertility: a comprehensive review. BJU Internat. 2011;108:1860–5. - PubMed
    1. Coward RM, Rajanahally S, Kovac JR, et al. Anabolic steroid induced hypogonadism in young men. J Urology. 2013;190:2200–5. - PubMed
    1. Rahnema CD, Lipshultz LI, Crosnoe LE, et al. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101:1271–9. - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Wiley full text link Wiley Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.


[8]ページ先頭

©2009-2025 Movatter.jp